Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Germ cell tumors belong to the most chemosensitive malignancies. Paclitaxel in combination
with ifosfamide and cisplatin (TIP) has become a common regimen for salvage treatment of germ
cell cancer.
Cabazitaxel may overcome resistance to docetaxel and paclitaxel and might have clinical
activity in patients with metastatic and progressive germ cell tumors.